Clinical trial
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract…
NCT00427219 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00427219 |
|---|---|
| Title | The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH) |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hypertrophy |
| Intervention type | Drug |
| Interventions | Ozarelix, Placebo |
| Enrollment | 74 |
| Start date | Jan 23, 2007 |
| Primary completion | Feb 27, 2008 |
| Completion | Feb 27, 2008 |
| First posted | Jan 26, 2007 |
| Last update posted | Oct 15, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: